That Page Has Moved But You Can Find It Below

Simply click on one of the links below to find its new location.

 

 

News and Analysis

  • Loxo Oncology and categories.php University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer
    Loxo Oncology and University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer Biopharmaceutical firm Loxo Oncology Inc. (NASDAQ:LOXO) and the University of Colorado Cancer Center has confirmed publication of research brief in online edition of journal Cancer Discovery showing the patient with tropomyosin receptor kinase fusion cancer enrolled in Phase 1 dose escalation trial of LOXO-101, only selective TRK inhibitor in clinical development.
  • ZIOPHARM Oncology Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma Biopharmaceutical firm ZIOPHARM Oncology Inc.(NASDAQ:ZIOP) Oncology has confirmed that U.S. Food and Drug Administration (FDA) has given approval to Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in treating the ones who suffer from malignant glioma.
More News

Subscriber Only Content

Newsletter

BioMedReports Abeona Announces Equity Financing; Aquinox to Provide Update on Phase 2 LEADERSHIP Trial in BPS/IC: Below is a... http://t.co/TbdS3gaTyr
5hreplyretweetfavorite
BioMedReports I see 'makings of protracted bear market': Gartman http://t.co/x8PS7JY96c
BioMedReports The Dow just broke a pretty dubious record http://t.co/hhVMQSrXvF

RSS Subscription